Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363116 · ClinicalTrials.gov registry record · Phase 4
A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
A Phase 4 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 298
- Enrollment target
NCT00363116 is a Phase 4 study that has completed, run by University of Cincinnati. The registered enrollment target is 298 participants.
The verdict
NCT00363116, a Phase 4 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 298 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and efficacy of two dosing regimens of daclizumab in simultaneous kidney/pancreas transplant recipients.
Interventions
- DRUG Daclizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 1999-04 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363116
The ClinicalTrials.gov registry entry for NCT00363116 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daclizumab is the first listed.
NCT00363116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00363116 about?
NCT00363116 is a clinical study titled "A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients". The purpose of the study is to determine the safety and efficacy of two dosing regimens of daclizumab in simultaneous kidney/pancreas transplant recipients.
What is the current status of trial NCT00363116?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 298 participants. The study started on 1999-04. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00363116?
The interventions under investigation include: Daclizumab (DRUG).
Who is sponsoring clinical trial NCT00363116?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.